About UNC93-like protein MFSD11
UNC93-like protein MFSD11 (MFSD11) is a protein
from Homo sapiens identified by UniProt accession
O43934, 449 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | UNC93-like protein MFSD11 |
| UniProt accession | O43934 |
| Gene | MFSD11 |
| Organism | Homo sapiens |
| Length | 449 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- acute myeloid leukemia · score 0.33
- atypical chronic myeloid leukemia, BCR-ABL1 negative · score 0.33
- acute megakaryoblastic leukemia in down syndrome · score 0.27
- PHF-tau measurement · score 0.26
- eye measurement · score 0.21
- mathematical ability · score 0.07
- alkaline phosphatase measurement · score 0.03
- neutrophil count · score 0.03
- esophageal squamous cell carcinoma · score 0.01
- Dravet syndrome · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43934-F1 | alphafold | PREDICTED | 87.74 | — |
Amino-acid sequence (449 residues)
MSPESKKLFN IIILGVAFMF MFTAFQTCGN VAQTVIRSLN RTDFHGSGYT SMAIIYGVFS ASNLITPSVV AIVGPQLSMF ASGLFYSMYI AVFIQPFPWS FYTASVFIGI AAAVLWTAQG NCLTINSDEH SIGRNSGIFW ALLQSSLFFG NLYIYFAWQG KTQISESDRR TVFIALTVIS LVGTVLFFLI RKPDSENVLG EDESSDDQDM EVNESAQNNL TKAVDAFKKS FKLCVTKEML LLSITTAYTG LELTFFSGVY GTCIGATNKF GAEEKSLIGL SGIFIGIGEI LGGSLFGLLS KNNRFGRNPV VLLGILVHFI AFYLIFLNMP GDAPIAPVKG TDSSAYIKSS KEVAILCSFL LGLGDSCFNT QLLSILGFLY SEDSAPAFAI FKFVQSICAA VAFFYSNYLL LHWQLLVMVI FGFFGTISFF TVEWEAAAFV ARGSDYRSI
Explore UNC93-like protein MFSD11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets